Table 2 Baseline cancer-related characteristics of the 122 RD patients with cancer and the 366 age-, sex-, and cancer-matched controls without RD

ECOG^c

 ≤1

28 (100.0)

81 (97.6)

1.000^b

22 (95.7)

45 (65.2)

0.006b

34 (77.3)

119 (89.5)

0.041^a

27 (100.0)

81 (100.0)

1.000^b

 ≥2

0 (0)

2 (2.4)

1.000^b

1 (4.3)

24 (34.8)

0.006b

10 (22.7)

14 (10.5)

0.041 ^a

0 (0)

0 (0)

1.000

Charlson^d

 0

16 (57.1)

54 (65.1)

0.501^b

8 (34.8)

46 (66.7)

0.025^b

22 (50.0)

90 (67.7)

0.047^a

18 (66.7)

65 (80.2)

0.188^b

 1

5 (17.9)

17 (20.5)

1.000^b

8 (34.8)

12 (17.4)

0.090^b

12 (27.3)

22 (16.5)

0.127b

4 (14.8)

11 (13.6)

1.000^b

 ≥2

7 (25.0)

12 (14.5)

0.246^a

7 (30.4)

11 (15.9)

0.141^b

11 (22.7)

21 (15.8)

0.180b

5 (18.5)

5 (6.2)

0.117^b

Stage

 I

13 (46.4)

41 (49.4)

0.830^b

7 (30.4)

12 (17.4)

0.234^b

14 (31.8)

27 (20.3)

0.149^b

14 (51.9)

24 (29.6)

0.036^a

 II

6 (21.4)

15 (18.1)

0.781^b

5 (21.7)

14 (20.3)

1.000^b

5 (11.4)

77 (57.9)

<0.001 ^b

10 (37.0)

44 (54.3)

0.120^a

 III

1 (3.6)

6 (7.2)

0.677^b

4 (17.4)

23 (33.3)

0.190^b

6 (13.6)

15 (11.3)

0.788 ^b

1 (3.7)

6 (7.4)

0.678^b

 IV

7 (25.0)

20 (24.1)

1.000^b

7 (30.4)

18 (26.1)

0.788^b

16 (36.4)

14 (10.5)

<0.001 ^b

2 (7.4)

2 (2.5)

0.260^b

 NA

1 (3.6)

1 (1.2)

0.443^b

0 (0)

2 (2.9)

1.000^b

3 (6.8)

0 (0)

0.015 ^b

0 (0)

5 (6.2)

0.328^b